A sensitive sample preparation pipeline for adventitious virus detection using Oxford Nanopore sequencing.

IF 4.6 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Molecular Therapy-Methods & Clinical Development Pub Date : 2025-04-24 eCollection Date: 2025-06-12 DOI:10.1016/j.omtm.2025.101478
Emmanuel K Tsinda, Charles A Swofford, James P B Strutt, José Sangerman, Raeuf Roushangar, Alexander Li, Lara M Gomez, Aidan N Bousquet, Caleb Neufeld, Jacqueline M Wolfrum, Jongyoon Han, Rohan B H Williams, Anthony J Sinskey, Paul W Barone, Stacy L Springs
{"title":"A sensitive sample preparation pipeline for adventitious virus detection using Oxford Nanopore sequencing.","authors":"Emmanuel K Tsinda, Charles A Swofford, James P B Strutt, José Sangerman, Raeuf Roushangar, Alexander Li, Lara M Gomez, Aidan N Bousquet, Caleb Neufeld, Jacqueline M Wolfrum, Jongyoon Han, Rohan B H Williams, Anthony J Sinskey, Paul W Barone, Stacy L Springs","doi":"10.1016/j.omtm.2025.101478","DOIUrl":null,"url":null,"abstract":"<p><p>Recent regulatory guidance now encourages the use of sequencing as an alternative adventitious agent testing assay to lengthy compendial <i>in vivo</i> assays used for cell line qualification. Most short-read sequencing assays, however, still require over a week to obtain a final test result since the sequencing must be completed before bioinformatic analysis can begin, which is still too long for some cell and gene therapy products that must be released as soon as possible to reach critically ill patients. Oxford Nanopore sequencing can address these issues, as it provides real-time basecalling and sequence alignment, which can reduce the overall assay time. Still, as with any sequencing platform, the abundance of background nucleic acid from the human or mammalian host can mask the signal from a low-level viral contaminant. To address this, we have developed a sensitive sample preparation workflow using concentration, nuclease treatment, and agnostic PCR methods to eliminate background signals and amplify viral contaminant reads, leading to a 3-log improvement in the limit of detection that is comparable to or better than short-read sequencing approaches. This approach will lead to more rapid and improved detection of viral contaminants in cell and gene therapy manufacturing.</p>","PeriodicalId":54333,"journal":{"name":"Molecular Therapy-Methods & Clinical Development","volume":"33 2","pages":"101478"},"PeriodicalIF":4.6000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229724/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy-Methods & Clinical Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtm.2025.101478","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/12 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Recent regulatory guidance now encourages the use of sequencing as an alternative adventitious agent testing assay to lengthy compendial in vivo assays used for cell line qualification. Most short-read sequencing assays, however, still require over a week to obtain a final test result since the sequencing must be completed before bioinformatic analysis can begin, which is still too long for some cell and gene therapy products that must be released as soon as possible to reach critically ill patients. Oxford Nanopore sequencing can address these issues, as it provides real-time basecalling and sequence alignment, which can reduce the overall assay time. Still, as with any sequencing platform, the abundance of background nucleic acid from the human or mammalian host can mask the signal from a low-level viral contaminant. To address this, we have developed a sensitive sample preparation workflow using concentration, nuclease treatment, and agnostic PCR methods to eliminate background signals and amplify viral contaminant reads, leading to a 3-log improvement in the limit of detection that is comparable to or better than short-read sequencing approaches. This approach will lead to more rapid and improved detection of viral contaminants in cell and gene therapy manufacturing.

利用牛津纳米孔测序技术检测外源病毒的灵敏样品制备管道。
最近的监管指南现在鼓励使用测序作为一种替代的不确定因子检测方法,以替代用于细胞系鉴定的冗长的药典体内检测方法。然而,由于测序必须在生物信息学分析开始之前完成,大多数短读测序分析仍然需要一周以上的时间才能获得最终测试结果,对于一些必须尽快发布以送达危重患者的细胞和基因治疗产品来说,这仍然太长了。牛津纳米孔测序可以解决这些问题,因为它提供实时的碱基调用和序列比对,这可以减少整体分析时间。然而,与任何测序平台一样,来自人类或哺乳动物宿主的丰富背景核酸可能掩盖来自低水平病毒污染物的信号。为了解决这个问题,我们开发了一种敏感的样品制备工作流程,使用浓度,核酸酶处理和不确定PCR方法来消除背景信号并放大病毒污染物读数,从而使检测极限提高3个对数,与短读测序方法相当或更好。这种方法将导致在细胞和基因治疗制造中更快速和改进的病毒污染物检测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Therapy-Methods & Clinical Development
Molecular Therapy-Methods & Clinical Development Biochemistry, Genetics and Molecular Biology-Molecular Biology
CiteScore
9.90
自引率
4.30%
发文量
163
审稿时长
12 weeks
期刊介绍: The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Topics of particular interest within the journal''s scope include: Gene vector engineering and production, Methods for targeted genome editing and engineering, Methods and technology development for cell reprogramming and directed differentiation of pluripotent cells, Methods for gene and cell vector delivery, Development of biomaterials and nanoparticles for applications in gene and cell therapy and regenerative medicine, Analysis of gene and cell vector biodistribution and tracking, Pharmacology/toxicology studies of new and next-generation vectors, Methods for cell isolation, engineering, culture, expansion, and transplantation, Cell processing, storage, and banking for therapeutic application, Preclinical and QC/QA assay development, Translational and clinical scale-up and Good Manufacturing procedures and process development, Clinical protocol development, Computational and bioinformatic methods for analysis, modeling, or visualization of biological data, Negotiating the regulatory approval process and obtaining such approval for clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信